The Ancient Chinese Medicine of Han Dynasty comes from the combination of traditional Chinese medicine. It can be used to treat mild, normal and severe pneumonia patients with New Coronavirus infection. It can also be used reasonably in the treatment of critically ill patients.
Prescription composition:
Ephedra, Cassia twig, Alisma Orientale, Atractylodes macrocephala, Poria cocos, Radix bupleuri, Aster, Chinese yam, FRUCTUS AURANTII IMMATURUS, Tangerine Peel etc.
On March 31, Phytomedicine, a journal of the first district of plant science and Pharmacy (SCI journal division of Chinese Academy of Sciences in 2020), published a research result of Professor Li Jing's team from Fuwai Hospital of Chinese Academy of Medical Sciences, National Center for cardiovascular disease, which was published on the international well-known medrxiv platform on December 27, 2020. Novel coronavirus pneumonia is recommended for the novel coronavirus pneumonia and the clinical efficacy of Qingfei detoxification soup is the most common clinical practice. The results of this study show that the mortality rate of the new crown pneumonia patients in Hubei province is reduced by half.
Novel coronavirus pneumonia was applied to the national health and Health Committee of China under the support of the Li Jing disease research and innovation project of New Coronavirus Academy of Medical Sciences, the Chinese Academy of Medical Sciences. The team extracted novel coronavirus pneumonia hospitalized electronic medical records from 15 designated hospitals in Hubei from January 2020 to May, and extracted data on clinical characteristics, treatment process and outcome. A total of 8939 novel coronavirus pneumonia patients were included in the study, 29% of which were treated with Ancient Chinese Medicine of Han Dynasty. The in-hospital mortality of patients who did not receive it was 4.8%, while the mortality of patients who received it was only 1.2%. After excluding the influence of the differences in clinical characteristics and other treatments between the two groups, the death risk of patients treated with Ancient Chinese Medicine of Han Dynasty was only half that of patients not treated with it. Moreover, no matter in different age groups and gender of patients, or in a variety of statistical analysis methods, there are the same differences in the risk of death between the two groups. In addition, there was no significant difference in the incidence of common adverse drug reactions such as acute liver and kidney injury between the two groups.
The study is the largest, multicenter clinical study of Ancient Chinese Medicine of Han Dynasty so far, which provides strong evidence for the significant efficacy of the drug in treating new crown pneumonia patients, and provides a scientific basis for the important role played by Chinese medicine in the prevention and treatment of the new crown pneumonia. The research team explored a variety of data extraction technologies, and adopted the mechanism of two person independent operation automatic extraction and a third person manual review, which effectively transformed the electronic medical records with different formats into scientific data for analysis, ensuring the data quality and reliable research results.
Post time: Apr-01-2021
